Cocaine abuse vaccine TA-CD

Drug Profile

Cocaine abuse vaccine TA-CD

Alternative Names: TA-CD; TA-CD09

Latest Information Update: 26 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmuLogic Pharmaceutical
  • Developer Celtic Pharma
  • Class Drug withdrawal therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cocaine abuse

Most Recent Events

  • 31 Aug 2010 Celtic Pharma and the National Institute on Drug Abuse initiate a phase II trial for Cocaine abuse in USA
  • 21 Jun 2006 Interim results from a phase IIb clinical trial in cocaine abuse have been added to the Drug Withdrawal therapeutic trials section
  • 17 Jun 2004 Clinical data from a media release have been added to the Drug Withdrawal immunogenicity and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top